Normunity

Normunity is a dynamic biotechnology company focused on pioneering novel anti-cancer therapies. Normunity is dedicated to addressing untapped biological mechanisms at the intersection of the immune system and tumor biology. This innovative approach targets the fundamental processes that influence tumor growth, immune surveillance evasion, and effective tumor clearance.

Normunity leverages these novel targets to develop a robust pipeline of cutting-edge anti-cancer medicines. This includes a diverse array of therapeutic antibodies, bispecific antibodies, and advanced payload-carrying biologics, positioning Normunity at the forefront of cancer therapeutics. The company’s lead program, NRM‑823, is a T cell engager featuring tumor-specific targeting for a broad spectrum of solid tumors, with clinical trials expected to commence in 2025. Normunity's offices are located in Boston, MA, and New Haven, CT.

Normunity is committed to innovation and excellence in biotechnology. We invite the management team at Normunity to further enhance your company’s profile by creating a customized and exclusive company showcase and product listing on our platform, highlighting the groundbreaking work being done at Normunity.